Journal Article

Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia

File, Thomas M., Das, Anita, Saviski, John, Talbot, George H., Gasink, Leanne B., Sweeney, Carolyn, Gelone, Steven P., Paukner, Susanne, Goldberg, Lisa, Seltzer, Elyse, Wicha, Wolfgang W.

2019

Overview

Monotherapy with lefamulin, a novel, pleuromutilin antibiotic with intravenous and oral formulation options, was noninferior to moxifloxacin for efficacy and generally safe and well tolerated for community-acquired bacterial pneumonia (CABP). Lefamulin’s spectrum of activity targets bacteria that cause CABP. Abstract Background Lefamulin, a pleuromutilin antibiotic, is active against pathogens commonly causing community-acquired bacterial pneumonia (CABP). The Lefamulin Evaluation Against Pneumonia (LEAP 1) study was a global noninferiority trial to evaluate the efficacy and safety of lefamulin for the treatment of CABP. Methods In this double-blind study, adults with CABP of Pneumonia Outcomes Research Team risk class ≥III were randomized 1:1 to receive lefamulin at 150 mg intravenously (IV) every 12 hours or moxifloxacin at 400 mg IV every 24 hours. After 6 doses, patients could be switched to an oral study drug if prespecified improvement criteria were met. If methicillin-resistant Staphylococcus aureus was suspected, either linezolid or placebo was added to moxifloxacin or lefamulin, respectively. The US Food and Drug Administration primary endpoint was an early clinical response (ECR) 96 ± 24 hours after the first dose of the study drug in the intent-to-treat (ITT) population (noninferiority margin, 12.5%). The European Medicines Agency co-primary endpoints were an investigator assessment of clinical response (IACR) 5–10 days after the last dose of the study drug in the modified ITT (mITT) and clinically evaluable (CE) populations (noninferiority margin, 10%). Results There were 551 patients randomized (n = 276 lefamulin; n = 275 moxifloxacin). Lefamulin was noninferior to moxifloxacin for ECR (87.3% vs 90.2%, respectively; difference −2.9%, 95% confidence interval [CI] g −8.5 to 2.8) and IACR (mITT, 81.7% vs 84.2%, respectively; difference −2.6%, 95% CI −8.9 to 3.9; CE, 86.9% vs 89.4%, respectively; difference −2.5%, 95% CI −8.4 to 3.4). Rates of study drug discontinuation due to treatment-emergent adverse events were 2.9% for lefamulin and 4.4% for moxifloxacin. Conclusions Lefamulin was noninferior to moxifloxacin for the primary efficacy endpoints and was generally safe and well tolerated. Clinical Trials Registration NCT02559310.

• Publisher: Oxford University Press
• Subject: Administration, Intravenous / Adult / Aged / and Commentaries / Anti-Bacterial Agents - administration & dosage / Anti-Bacterial Agents - adverse effects / Anti-Bacterial Agents - therapeutic use / ARTICLES AND COMMENTARIES / Diterpenes - administration & dosage / Diterpenes - adverse effects / Diterpenes - therapeutic use / Double-Blind Method / Female / Humans / Linezolid - adverse effects / Linezolid - therapeutic use / Male / Microbial Sensitivity Tests / Middle Aged / Moxifloxacin - administration & dosage / Moxifloxacin - adverse effects / Moxifloxacin - therapeutic use / Pleuromutilins / Pneumonia, Bacterial - drug therapy / Pneumonia, Bacterial - metabolism / Polycyclic Compounds - administration & dosage / Polycyclic Compounds - adverse effects / Polycyclic Compounds - therapeutic use / Randomized Controlled Trials as Topic / Thioglycolates - administration & dosage / Thioglycolates - adverse effects / Thioglycolates - therapeutic use